Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Gastroenterology. Author manuscript; available in PMC 2009 July 31.
Published in final edited form as:
PMCID: PMC2719297


Andrew T. Chan, M.D., M.P.H.,1,2 Edward L. Giovannucci, M.D., Sc.D.,2,3,4,5 Jeffrey A. Meyerhardt, M.D., M.P.H.,3,6 Eva S. Schernhammer, M.D., Dr. PH,2 Kana Wu, M.D., Ph.D,5 and Charles S. Fuchs, M.D., M.P.H.2,3,6


Background and Aims

Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited.


We conducted a prospective study of 47,363 male health professionals who were ages 40–75 years at enrollment in 1986. Biennially, we collected data on aspirin use, other risk factors, and diagnoses of colorectal cancer. We confirmed all reports of colorectal cancer through 2004 by review of medical records.


During 18 years of follow-up, we documented 975 cases of colorectal cancer over 761,757 person-years. After adjustment for risk factors, men who regularly used aspirin (≥2 times/week) had a multivariate relative risk (RR) for colorectal cancer of 0.79 (95% confidence interval, [CI], 0.69–0.90), compared with non-regular users. However, significant risk reduction required at least 6–10 years of use (Ptrend=0.008) and was no longer evident within 4 years of discontinuing use (multivariate RR, 1.00; CI, 0.72–1.39). The benefit appeared related to increasing cumulative average dose: compared to men who denied any aspirin use, the multivariate RRs for cancer were 0.94 (CI, 0.75–1.18) for men who used 0.5–1.5 standard aspirin/week, 0.80 (CI, 0.63–1.01) for 2–5 aspirin/week, 0.72 (CI, 0.56–0.92) for 6–14 aspirin/week, and 0.30 (CI, 0.11–0.81) for >14 aspirin/week (Ptrend=0.004).


Regular, long-term aspirin use reduces risk of colorectal cancer among men. However, the benefit of aspirin necessitates at least 6 years of consistent use with maximal risk reduction at doses greater than 14 tablets/week. The potential hazards associated with long-term use of such doses should be carefully considered.

Keywords: Colorectal Neoplasms, Colorectal Cancer, Aspirin, Non-steroidal Anti-inflammatory Drugs, Epidemiology, Risk Factors, Prospective Study

Three randomized, placebo-controlled trials have demonstrated that short-term aspirin use reduces the risk of adenoma recurrence in patients with a prior history of colorectal neoplasia.13 However, the influence of aspirin on cancer risk is less certain. Two large randomized trials, the Physicians’ Health Study and the Women’s Health Study, failed to show a protective benefit of low-dose aspirin on risk of colorectal cancer in men and women, respectively.4, 5 As noted by a recent systematic review for the U.S. Preventive Services Task Force,6 the failure of aspirin in these latter two trials may reflect the low doses of aspirin used or insufficient duration of treatment or follow-up. In support of this explanation, a recent secondary analysis of data pooled from two other randomized trials of higher doses of aspirin did observe a protective benefit for colorectal cancer with long-term use.7 Ultimately, well-designed studies examining the optimal dose of aspirin for chemoprevention has been identified as a high priority.6

Thus, we examined the influence of aspirin on the risk of colorectal cancer among men enrolled in a large prospective cohort study which provides detailed and updated information on aspirin use (the Health Professionals Follow-up Study). This population permitted a more comprehensive examination of the effect of long-term aspirin use at a wide range of doses on the primary prevention of sporadic colorectal cancer than would be feasible in a placebo-controlled trial. An earlier examination of aspirin use and colorectal cancer in this cohort did observe an inverse association; however, that analysis was limited by the number of overall cases (251), short follow-up (6 years), and the lack of information on aspirin dose.8 In the present study, we offer results that encompass 18 years of follow-up with 975 documented cases of colorectal cancer, and include data on aspirin dose.


Study Population

The Health Professionals Follow-up Study (HPFS) is a cohort of 51,529 U.S. male dentists, optometrists, osteopaths, podiatrists, pharmacists, and veterinarians, who returned a mailed health questionnaire in 1986. Participants were 40 to 75 years of age at entry. The questionnaire included a validated assessment of diet,9 aspirin use, as well as medical diagnoses, including cancer. With a follow-up rate exceeding 90%, we have mailed biennial questionnaires to update information and identify newly diagnosed cases of cancer. The institutional review board at the Harvard School of Public Health approved this study.

Assessment of Medication Use

In the 1986 questionnaire and every two years thereafter, we inquired if men used aspirin, two or more times per week (“e.g. Anacin, Bufferin, Alka-Seltzer”), acetaminophen two or more times per week (“e.g. Tylenol”), and other anti-inflammatory medications (“e.g. Motrin, Indocin, Naprosyn, Dolobid”). We did not collect information on individual NSAID types. Beginning in 1992, we also asked men the average number of aspirin tablets used per week (in categories). Early in the study, most men used standard-dose aspirin tablets of 325 mg;8 however, to reflect overall secular trends in consumption of low-dose, or baby aspirin, questionnaires after 1992 asked participants to convert intake of four baby aspirin to one adult tablet. The reasons for aspirin use were not assessed for the entire cohort, but a supplementary questionnaire was sent in 1993 to a sample of 211 men who reported aspirin use from 1986 to 1990 (88% response). The major reasons for use were cardiovascular disease, 25.4%; to decrease risk for cardiovascular disease, 58.4%; headaches, 25.4%; joint or musculoskeletal pain, 33.0%; and other reasons 7.0%.8

Ascertainment of Cases

We requested written permission to acquire medical records and pathology reports from men who reported colorectal cancer on our biennial questionnaire. We identified deaths with over 96% sensitivity through the National Death Index and next-of-kin.10 For all deaths attributable to colorectal cancer, we requested permission from next-of-kin to review medical records. A study physician, blinded to exposure information, reviewed records to extract information on histological type, anatomic location, and stage of the cancer. We classified stage of cancer according to the 6th version of the American Joint Committee on Cancer.11

Statistical Analysis

At baseline, we excluded men with a history of cancer (except non-melanoma skin cancer), inflammatory bowel disease, a familial polyposis syndrome, or recorded implausible dietary data (outside the range of 800 to 4200 kcal/d). After these exclusions, 47,363 men were eligible for analysis and accrued follow-up time beginning on the month of return of the baseline 1986 questionnaire and ending on the month of diagnosis of colorectal cancer, month of death from other causes, or January 1, 2004, whichever came first. We recognized that participants may have varied their use of aspirin over the 18-year study period. Thus, we utilized time-varying covariates such that each individual participant contributed person-time according to the aspirin data they provided on each biennial questionnaire. Consistent with previous analyses of this cohort, men who reported using aspirin 2 more times per week were defined as regular users whereas those who reported less aspirin use were defined as non-regular users. 8, 12 As previously described,12, 13 for our dose analyses, we calculated a cumulative average intake of aspirin as reported on all available questionnaires up to the start of each 2-year follow-up interval to reduce in-person variation and better estimate long-term intake. We examined duration of aspirin use by calculating the number of years of use according to response to all biennial questionnaires prior to each 2-year follow-up interval.13, 14

We calculated incidence rates of colorectal cancer for men in a specific category of aspirin use by dividing the number of incident cases by the number of person-years. We computed relative risks (RR) by dividing the incidence rate of disease in one category divided by the incidence rate in the reference category. We used Cox proportional hazards modeling control for multiple variables simultaneously and to compute 95% confidence intervals (CI). Age was controlled using 1-year categories and calendar time in 2-year intervals as stratified variables in the Cox models. Consistent with our prior studies, 13 all multivariate relative risks were adjusted for risk factors previously shown to be associated with colorectal cancer risk in this cohort.1518 We used the most updated information for all covariates prior to each 2-year interval. We used SAS version 9.1.3 (Cary, NC) for all analyses. All P values are two-sided.


Among the 47,363 eligible men, we documented 975 cases of colorectal cancer over 761,757 person-years. At baseline, compared to participants who denied aspirin use, men reporting regular use (≥2 times per week) were older, more likely to previously smoke, and more likely to regularly use multivitamins. In addition, men who reported regular aspirin intake consumed slightly more alcohol and folate (TABLE 1).

Table 1
Baseline Characteristics of the Study Cohort in 1986*

Compared to men who denied regular use, participants reporting regular aspirin use experienced a significantly lower risk of colorectal cancer (multivariate RR, 0.79; 95% CI, 0.69–0.90), even after controlling for other colorectal cancer risk factors (TABLE 2). The effect was similar for distal colon cancers, proximal colon cancers, and rectal cancers. In addition, regular use of aspirin appeared to offer a significant reduction in risk of both early (stage 1 and 2) cancers (multivariate RR, 0.80; 95% CI, 0.66–0.96) and advanced (stage 3 and 4) cancers (multivariate RR, 0.74; 95% CI, 0.59–0.92).

Table 2
Relative Risk of Colorectal Cancer According to Regular Use of Aspirin*

We assessed the effect of duration of regular aspirin use on colorectal cancer risk (TABLE 3). Compared to participants who abstained from regular use, aspirin use for five or fewer years did not confer a significant reduction in risk. However, beyond 5 years, we observed a significant reduction in risk with longer duration of use (P for trend=0.008). Notably, for early (stage 1) cancers, the influence of aspirin did not appear stonger with increasing duration of use; compared to men who denied regular use, the multivariate RRs for stage 1 cancer were 0.77 (95% CI, 0.55–1.07) for men reporting regular use for up to 5 years and 0.81 (95% CI, 0.60–1.09) for greater than 5 years (P for trend=0.31). In contrast, for more advanced cancers (stages 2 to 4), the benefit of aspirin did appear to increase with longer duration of use. The multivariate RRs for stage 2 cancer were 1.04 (95% CI, 0.72–1.52) for men who used for up to 5 years and 0.68 (95% CI, 0.47–0.98) for greater than 5 years (P for trend=0.03). Similarly, the multivariate RRs for stage 3 and 4 cancers were 0.90 (95% CI, 0.67–1.19) for 5 or fewer years and 0.67 (95% CI, 0.52–0.88) for greater than 5 years (P for trend = 0.005).

Table 3
Relative Risk of Colorectal Cancer According to Duration of Aspirin Intake*

To evaluate if the effect of aspirin required consistent use, we also examined the risk of colorectal cancer according to time since discontinuation of regular use (TABLE 4). Compared to participants who had never used aspirin regularly, the multivariate RR among participants who had stopped regular use less than four years in the past was 0.82 (95% CI, 0.64–1.06). The multivariate RR among those who had discontinued regular use four to five years in the past was 1.00 (95% CI, 0.72–1.39), comparable to those who had never used regularly.

Table 4
Relative Risk of Colorectal Cancer According to Time Since Discontinuation of Aspirin Intake*

The apparent benefit associated with aspirin use was substantially greater with increasing dose (TABLE 5). Compared to participants who took no aspirin, men who used the equivalent of 0.5–1.5 standard (325 mg) tablets of aspirin per week did not have a significantly lower risk of colorectal cancer (multivariate RR, 0.94; 95% CI, 0.75–1.18). However, men reporting 6 to 14 standard aspirin tablets per week experienced a multivariate RR of 0.72 (95% CI, 0.56–0.92), and those consuming more than 14 tablets per week experienced a multivariate RR of 0.30 (95% CI, 0.11–0.81; P for trend=0.004). We considered the possibility that the influence of aspirin dose was due to a longer duration of aspirin use among men taking higher doses. However, when we additionally controlled for the duration of aspirin use, the effect of aspirin dose remained significant (P for trend=0.03).

Table 5
Relative Risk of Colorectal Cancer According to Dose of Aspirin Intake*

We also evaluated the influence of non-aspirin NSAIDs on colorectal cancer risk. Compared to non-regular users, we did not observe any reduction in risk with regular use of NSAIDs for 1 to 5 years (multivariate RR 0.88; 95% CI, 0.73–1.06). However, there was a significant reduction in risk among men who used NSAIDs greater than 5 years (multivariate RR, 0.72; 95%, 0.55–0.94; P for trend=0.008). To assess whether these associations reflected a non-specific analgesic effect, we also examined the influence of regular acetaminophen use on colorectal cancer risk. We did not observe an association with colorectal cancer risk among men who regularly used acetaminophen for 1 to 5 years (multivariate RR, 0.98; 95% CI, 0.78–1.22) or among men who regularly used acetaminophen for greater than 5 years (multivariate RR, 0.89; 95% CI, 0.65–1.22; P for trend=0.32).

Finally, we confirmed that risk factors associated with a lower risk of colorectal cancer were similarly associated in this analysis, including screening endoscopy, regular use of multivitamins, and high dietary intake of folate and calcium (P<0.05 for all comparisions). On the other hand, family history of colorectal cancer, early smoking history, alcohol intake, and high intake of red meat were associated with an increased risk of colorectal cancer (P<0.05 for all comparisons). In this cohort, each of these risk factors have been shown to be associated independently with risk of colorectal cancer in prior detailed analyses.1518


In an average-risk population of men, we found that long-term, regular aspirin use (≥2 times per week) was associated with a significant reduction in the risk of colorectal cancer. Notably, the benefit of aspirin was not apparent until after more than five years of use, and the greatest reduction in risk was observed at cumulative doses of more than 14 standard tablets per week. In addition, regular use of non-aspirin NSAIDs for more than 5 years was associated with a comparable risk reduction. We observed a similar risk reduction for cancers in all anatomic sites of the large bowel and for cancers of all stages. Although our study was limited to men, we have previously demonstrated a similar protective association for aspirin in women.13, 14

Our results are supported by three intervention trials of patients with prior colorectal adenoma or cancer that have demonstrated a benefit to aspirin use on the subsequent risk of adenoma.13 However, these prior trials were unable to define the optimal chemopreventive dose of aspirin. One trial demonstrated that both 160 mg and 300 mg of daily soluble aspirin was effective; 3 a second trial, which examined only one dose, showed that standard-dose aspirin (325 mg) reduced risk;2 and finally, a third trial did not observe any reduction in adenoma recurrence with standard-dose aspirin but did observe a moderate benefit with low-dose (81 mg) aspirin.1

In contrast to trials of adenoma recurrence, the Women’s Health Study, a randomized trial of aspirin specifically designed to examine incidence of total cancer and cardiovascular events, did not demonstrate a significant benefit for colorectal cancer (a secondary endpoint) after 10 years of treatment.4 A secondary analysis of the Physicians’ Health Study, a trial of aspirin in the prevention of cardiovascular disease, also did not observe any association with colorectal cancer among men after 5 years of treatment.5 Although our findings might appear to conflict with these observations, both the Women’s Health Study and Physician’s Health Study used relatively low-dose aspirin (100 to 325 mg every other day). In our cohort, similar doses of aspirin also had no effect on the risk of colorectal cancer (multivariate RR, 0.94; 95% CI 0.75–1.18), although higher doses (>6 standard tablets/week) did confer progressively greater reductions in cancer risk. Taken together, these data suggest that aspirin at a dose equivalent to 50–162.5 mg per day, over 5–10 years of treatment, appears to be inadequate for prevention of colorectal cancer.4, 5, 13

A recent analysis of pooled data from the British Doctors’ Trial and the UK-TIA Trial further support our findings on the necessary dose of aspirin to reduce risk of colorectal cancer. Randomization to higher doses of aspirin (300 mg to 1200 mg per day) was associated with a significant reduction in risk of colorectal cancer, and the significant benefit associated with aspirin was not apparent until at least 10 years of follow-up.7 Several lines of evidence support our findings that the anti-cancer benefit of aspirin is highly dose-dependent. First, experimental data demonstrate that higher doses are needed to inhibit the COX-2 isoenzyme,19 which is directly relevant to colorectal neoplasia.20 Previous data from this cohort have also confirmed the importance of inhibition of COX-2 in mediating the anti-cancer benefit of aspirin.12 Second, other non-COX-mediated mechanisms associated with aspirin are also maximized at higher doses.2126 Third, randomized trials of the COX-2 inhibitor celecoxib demonstrated that higher doses are more effective in reducing adenoma burden in patients with familial polyposis subjects or prior high-risk adenoma.27, 28 Other epidemiological studies generally have found consistent dose relationships for both adenoma 2933 and cancer.13, 29, 3438

Although short-term use of aspirin appears to reduce risk of adenoma,13, 32 we observed that an overall reduction in risk of cancer required more than five years of use. However, because we did not collect data on the number of years of aspirin use at study baseline, duration of use was probably somewhat underestimated. A previous supplementary questionnaire in a subset of regular aspirin users in the present study found that the median duration of use prior the baseline questionnaire was at least 5 years.8 Thus, it is likely that the minimum duration of use necessary to observe a risk reduction may be comparable to the 10 years we observed in a parallel cohort of women.13 Our results highlighting the necessity of long-term use in reducing risk of colorectal cancer are again supported by findings from the pooled United Kingdom randomized trials as well as other cohorts.7, 3840

Given our present understanding of the prolonged latency underlying the adenoma-carcinoma pathway, our findings of an overall duration effect are consistent with aspirin having a greater influence on initiation or early promotion of incident neoplasia rather than on progression of established tumors. Our findings across cancer stages support this hypothesis: longer duration was required for an effect of aspirin to become apparent on advanced cancers (stage 2–4) but not early (stage 1) cancers.

Consistent with a prior study of a general practice database,36 we also observed that a benefit to aspirin use appears to diminish less than 4 years after discontinuing use and is no longer evident after 4–5 years of discontinuing use. This observation suggests that the need for long-term use not only reflects the importance of initiating aspirin in the earliest stages of carcinogenesis, but also the necessity for sustained, uninterrupted therapy.

In analyses by anatomic subsite, it appeared that the effect of aspirin was more weakly associated with cancers of the proximal or distal colon as compared with rectum. However, these findings should be interpreted with caution given the limited number of cases within each subsite. Further studies should examine the potential for a differential effect of aspirin based on anatomic location which may be related to differences in the molecular characteristics of tumors.41

Although previous studies have demonstrated an inverse relationship between aspirin and colorectal cancer, 7, 8, 14, 29, 3540, 4254 the present study differs in several important ways. First, because we collected detailed, updated information on aspirin at a range of doses over 18 years of follow-up, we were able to evaluate long-term use across a broad range of intake. Second, we obtained aspirin data prospectively, prior to diagnosis. Thus, any errors in recall would have tended to attenuate rather than exaggerate true associations and biases related to incomplete data collection from participants with fatal diagnoses were minimized. Third, since participants were all health professionals, the accuracy of self-reported aspirin use is likely to be high and more likely to reflect actual consumption. However, we acknowledge this may also limit the generalizability of our findings to other populations. Fourth, we used time-varying, biennially updated aspirin data in our Cox models to account for the effect of changes in aspirin use over time on risk of colorectal cancer. Finally, we also collected detailed data on potential confounders and had a high follow-up response rate.

Our study was observational and aspirin use was self-selected. However, our results have strong biological plausibility and causality has been demonstrated in three intervention trials of adenoma recurrence and a pooled analysis of randomized trials of aspirin linked with outcomes derived from a cancer registry. Our data are also remarkably consistent with findings among a distinct, large, prospective cohort of women who used aspirin less frequently for cardiovascular indications. Moreover, acetaminophen, an analgesic used for similar maladies but with a distinct mechanism of action, did not appear to be related to colorectal cancer and adjustment for a wide range of risk factors had minimal influence on our findings, suggesting little potential for residual or uncontrolled confounding.

Our results are not as definitive as a randomized, intervention trial designed to evaluate the effect of various doses of aspirin on colorectal cancer risk. However, such a trial is not likely to be feasible given the need for a large number of participants and prolonged follow-up, as well as ethical concerns given the efficacy of currently accepted screening practices. Nonetheless, when viewed in the context of the preponderance of laboratory studies, epidemiological data, adenoma recurrence trials, and the United Kingdom trials, our data do provide convincing evidence that aspirin can reduce the incidence of colorectal cancer.6 Most importantly, our study provides additional support that aspirin chemoprevention requires use of higher doses over a long period, which raises the risk of adverse events such as gastrointestinal bleeding. Thus, our results suggest that aspirin cannot be recommended for general use by a healthy population for cancer prevention, which is consistent with the conclusions of the U.S. Preventative Services Task Force. 55

In conclusion, our study demonstrates that aspirin is associated with a reduced risk of colorectal cancer, but requires long-term, consistent use with maximal risk reduction at doses considerably higher than those recommended to prevent cardiovascular disease. These data support the need to further characterize those for whom the potential benefits of aspirin outweigh the hazards and to improve our understanding of the mechanisms by which aspirin inhibits carcinogenesis. Such studies may lead to a tailored approach to chemoprevention and highlight additional targets for prevention with future agents that may have more favorable risk-benefit profiles.


This study was presented in abstract form at Digestive Disease Week 2007 in Washington, D.C. on May 20, 2007. The authors would like to acknowledge the continued dedication of the participants in the Health Professionals Follow-up Study.

Funding/Support: Supported by grants (CA55075) from the National Cancer Institute, National Institutes of Health, and the Entertainment Industry Foundation National Colorectal Cancer Research Alliance. Dr. Chan is a recipient of the American Gastroenterological Association/Foundation for Digestive Health and Nutrition Research Scholar Award and a career development award from the National Cancer Institute (CA10741). Dr. Chan also has a career development award from the Glaxo Institute for Digestive Health for an unrelated study and a career development award from the National Cancer Institute (CA107412).

Role of the Sponsor: The National Cancer Institute, the National Institutes of Health, the Entertainment Industry Foundation National Colorectal Cancer Research Alliance, the American Gastroenterological Association, and the Foundation for Digestive Health and Nutrition had no role in the collection, management, analysis, or interpretation of the data, and had no role in the preparation, review, or approval of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health, the Entertainment Industry Foundation National Colorectal Cancer Research Alliance, the American Gastroenterological Association, and the Foundation for Digestive Health and Nutrition.


All authors have no conflict of interests to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9. [PubMed]
2. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90. [PubMed]
3. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328–36. [PubMed]
4. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. Jama. 2005;294:47–55. [PubMed]
5. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4. [PubMed]
6. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:365–75. [PubMed]
7. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13. [PubMed]
8. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–6. [PubMed]
9. Rimm E, Giovannucci E, Stampfer M, Colditz G, Litin L, Willett W. Reproducibility and validity of an expanded self-administered semiquantitative food questionnaire among health professionals. Am J Epidemiol. 1992;135:1114–1126. [PubMed]
10. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, Hennekens CH. Test of the National Death Index. Am J Epidemiol. 1984;119:837–839. [PubMed]
11. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M. AJCC Cancer Staging Handbook. Springer-Verlag; 2002.
12. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–42. [PubMed]
13. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Jama. 2005;294:914–23. [PMC free article] [PubMed]
14. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–14. [PubMed]
15. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11:579–88. [PubMed]
16. Kavanagh AM, Giovannucci EL, Fuchs CS, Colditz GA. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control. 1998;9:455–62. [PubMed]
17. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst. 2002;94:437–46. [PubMed]
18. Fuchs C, Giovannucci E, Colditz G, Hunter D, Speizer F, Willett W. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669–1674. [PubMed]
19. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83. [PubMed]
20. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8. [PubMed]
21. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–9. [PubMed]
22. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16. [PubMed]
23. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998;95:681–6. [PubMed]
24. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335–45. [PMC free article] [PubMed]
25. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274:27307–14. [PubMed]
26. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60:6846–50. [PubMed]
27. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52. [PubMed]
28. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84. [PubMed]
29. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci. 1996;41:1319–26. [PubMed]
30. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376–81. [PubMed]
31. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, Burt R, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin A. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States) Cancer Causes and Control. 2003;14:403–411. [PubMed]
32. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GC, Hunter DJ, Willett WC, Fuchs CS. A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med. 2004;140:157–166. [PubMed]
33. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst. 2005;97:457–60. [PubMed]
34. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88:1687–92. [PMC free article] [PubMed]
35. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72:1171–7. [PubMed]
36. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88–93. [PubMed]
37. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994;154:394–9. [PubMed]
38. Larsson SC, Giovannucci E, Wolk A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer. 2006;95:1277–9. [PMC free article] [PubMed]
39. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW., Jr Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–7. [PubMed]
40. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99:608–15. [PubMed]
41. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999;45:730–2. [PMC free article] [PubMed]
42. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–404. [PubMed]
43. Thun M, Calle E, Namboodiri M, Heath C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–1596. [PubMed]
44. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83:355–8. [PubMed]
45. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138–46. [PubMed]
46. Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci. 1994;39:2480–4. [PubMed]
47. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994;74:1847–54. [PubMed]
48. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996;5:955–60. [PubMed]
49. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A. Aspirin and colorectal cancer. Br J Cancer. 1997;76:675–7. [PMC free article] [PubMed]
50. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer. 1998;82:2326–33. [PubMed]
51. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81:62–8. [PMC free article] [PubMed]
52. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642–6. [PMC free article] [PubMed]
53. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control. 2000;11:249–55. [PubMed]
54. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2006;15:1785–90. [PubMed]
55. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–4. [PubMed]